机器人辅助根治性膀胱切除术后尿路感染的预防性抗生素
预防性使用抗生素能降低机器人辅助根治性膀胱切除术后尿路感染的发生率吗
This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
I. To determine if the utilization of a prophylactic antibiotic during the postoperative period will decrease the rate of urinary tract infection (UTI) post robot-assisted radical cystectomy.
SECONDARY OBJECTIVE:
I. To identify pre- and post-operative factors that may be associated with the development of a 90-day UTI following radical cystectomy.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (ANTIBIOTIC): Patients receive ertapenem Intravenously (IV), levofloxacin, or clindamycin IV at induction per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
GROUP II (CONTROL): Patients receive ertapenem IV, levofloxacin IV or clindamycin IV at induction per standard of care.
After surgery, patients are followed up to 120 days.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
New York
-
Buffalo、New York、美国、14263
- Roswell Park Cancer Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Any patient that electively chooses to have a cystectomy is eligible to participate in the study. Indications for a person who may undergo a cystectomy include having a diagnosis of muscle-invasive bladder cancer (MIBC) or refractory non-muscle invasive bladder cancer (NMIBC)
- Any patient that will electively choose to have a robot-assisted radical cystectomy and is able to provide consent
- Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Patients with a history of myasthenia gravis
- Patients with a history of QT prolongation or taking other drugs that prolong corrected QTc (QTc) should be excluded
- Patients with renal dysfunction, creatinine clearance (mL/min) < 30
- Pregnant or nursing female participants
- Females who receive a fertile sex sparing robot-assisted radical cystectomy (RARC)
- Unwilling or unable to follow protocol requirements
- Patients who receive a prophylactic antibiotic or antibiotic for any other reason prior to discharge
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic. |
Given PO
其他名称:
Complete drug diary Given PO Given PO
其他名称:
Given PO
其他名称:
Given PO
其他名称:
|
|
有源比较器:Group II (standard of care)
Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. |
Given PO
其他名称:
Given PO Given PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Urinary Tract Infection (UTI)
大体时间:At 90 days after surgery
|
The number of paticipants who experienced UTI (primary outcome) within 90 days after cystectomy is reported for each group. |
At 90 days after surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Infection
大体时间:Up to 90 days after surgery
|
Number of participants who experienced infectious complication(s) within 90 days after cystectomy is reported for each group. This includes UTI (primary outcome) and other types of infections, such as intraabdominal infection, wound infection, fungal infection, etc. |
Up to 90 days after surgery
|
合作者和调查者
调查人员
- 首席研究员:Khurshid A Guru、Roswell Park Cancer Institute
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 男性泌尿生殖系统疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 感染
- 泌尿系肿瘤
- 膀胱疾病
- 膀胱肿瘤
- 尿路感染
- 硫化合物
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 药物制剂
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 碳氢化合物,芳香族
- 糖苷
- 酰胺
- 苯胺化合物
- 胺
- 嘧啶
- 苯衍生物
- 吡咯烷
- 林霉素
- 林肯酰胺
- 药物组合
- β-内酰胺
- Lactams
- 氟喹诺酮
- 4- Quinolones
- 喹诺酮
- 奎诺琳
- 硝基化合物
- 亚甲氧唑
- 苯甲氟二酰胺
- 磺酰胺
- 磺基酰胺
- 硫酮
- 甲氧苄啶
- 碳青霉烯
- 弗拉斯
- 硝化呋喃
- 厄他培南
- 克林霉素
- 甲氧苄啶、磺胺甲恶唑药物组合
- 左氧氟沙星
- 呋喃妥因
- 氧氟沙星
其他研究编号
- I 573720
- I 573720 (其他标识符:Roswell Park Cancer Institute)
- NCI-2020-04928 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.